

PRECEPT – PRostatE CancEr Prognosis and Treatment



Supported by



Victorian Comprehensive Cancer Centre partners



A team with the necessary expertise....

Role	Name	Level	Site	Specialty
PI	Niall Corcoran	MCR	VCCC, VIC	Urology
CI	Paul Boutros	SR	UCLA, US	Genomics
CI	Rob Bristow	SR	UMAN, UK	RadOnc
CI	Maggie Centenera	MCR	SAHMRI, SA	Tumour Biology
CI	Ian Collins	MCR	VCCC, VIC	MedOnc
CI	Ros Eeles	SR	ICR, UK	ClinOnc
CI	Vanessa Hayes	SR	Garvan, NSW	Genomics
CI	Chris Hovens	SR	UOM, VIC	Tumour Biology
CI	Maarten Ijzerman	SR	UOM, VIC	Health Services
CI	Tony Papenfuss	SR	WEHI, VIC	Bio-informatics
CI	Belinda Parker	MCR	LaTrobe, VIC	Immuno-oncology

Role	Name	Level	Site	Specialty
CI	Daniel Park	MCR	UOM, VIC	Bio-informatics
CI	Bernie Pope	MCR	UOM, VIC	Bio-informatics
CI	Chris Sweeney	SR	DFCC, USA	MedOnc
CI	Ben Tran	MCR	PMCI, VIC	MedOnc
AI	Anis Hamid	ECR	UOM, VIC	MedOnc
AI	Ben Thomas	ECR	RMH, VIC	Urology
AI	Edmond Kwan	ECR	MU, VIC	MedOnc
RTM	Tony Costello	SR	RMH, VIC	Urology
RTM	Stefan Heinze	SR	RMH, VIC	Radiology
RTM	Joseph Ischia	MCR	Austin, VIC	Urology
RTM	Phillip Stricker	SR	StV, NSW	Urology

A team with the necessary expertise that already works together

Role	Name	Level	Site	Specialty
PI	Niall Corcoran	MCR	VCCC, VIC	Urology
CI	Paul Boutros	SR	UCLA, US	Genomics
CI	Rob Bristow	SR	UMAN, UK	RadOnc
CI	Maggie Centenera	MCR	SAHMRI, SA	Tumour Biology
CI	Ian Collins	MCR	VCCC, VIC	MedOnc
CI	Ros Eeles	SR	ICR, UK	ClinOnc
CI	Vanessa Hayes	SR	Garvan, NSW	Genomics
CI	Chris Hovens	SR	UOM, VIC	Tumour Biology
CI	Maarten Ijzerman	SR	UOM, VIC	Health Services
CI	Tony Papenfuss	SR	WEHI, VIC	Bio-informatics
CI	Belinda Parker	MCR	LaTrobe, VIC	Immuno-oncology


Role	Name	Level	Site	Specialty
CI	Daniel Park	MCR	UOM, VIC	Bio-informatics
CI	Bernie Pope	MCR	UOM, VIC	Bio-informatics
CI	Chris Sweeney	SR	DFCC, USA	MedOnc
CI	Ben Tran	MCR	PMCI, VIC	MedOnc
AI	Anis Hamid	ECR	UOM, VIC	MedOnc
AI	Ben Thomas	ECR	RMH, VIC	Urology
AI	Edmond Kwan	ECR	MU, VIC	MedOnc
RTM	Tony Costello	SR	RMH, VIC	Urology
RTM	Stefan Heinze	SR	RMH, VIC	Radiology
RTM	Joseph Ischia			
RTM	Phillip Stricker			




A team with the necessary expertise that already works together

Role	Name	Level	Site	Specialty
PI	Niall Corcoran	MCR	VCCC, VIC	Urology
CI	Paul Boutros	SR	UCLA, US	Genomics
CI	Rob Bristow	SR	UMAN, UK	RadOnc
CI	Maggie Centenera	MCR	SAHMRI, SA	Tumour Biology
CI	Ian Collins	MCR	VCCC, VIC	MedOnc
CI	Ros Eeles	SR	ICR, UK	ClinOnc
CI	Vanessa Hayes	SR	Garvan, NSW	Genomics
CI	Chris Hovens	SR	UOM, VIC	Tumour Biology
CI	Maarten Ijzerman	SR	UOM, VIC	Health Services
CI	Tony Papenfuss	SR	WEHI, VIC	Bio-informatics
CI	Belinda Parker	MCR	LaTrobe, VIC	Immuno-oncology


Role	Name	Level	Site	Specialty
CI	Daniel Park	MCR	UOM, VIC	Bio-informatics
CI	Bernie Pope	MCR	UOM, VIC	Bio-informatics
CI	Chris Sweeney	SR	DFCC, USA	MedOnc
CI	Ben Tran	MCR	PMCI, VIC	MedOnc
AI	Anis Hamid	ECR	UOM, VIC	MedOnc
AI	Ben Thomas	ECR		
AI	Edmond Kwan	ECR		
RTM	Tony Costello	SR		
RTM	Stefan Heinze	SR		
RTM	Joseph Ischia	MCR		
RTM	Phillip Stricker	SR		




Natural History of Prostate Cancer



Natural History of Prostate Cancer



Current Practice in Australia



Prostate Cancer-Specific
Mortality



9%

Lived *because*
of treatment




17%

Died regardless
of treatment

PCOR-Vic
SPCG-4

Research Program

Aim 1




Minimize Unnecessary Treatment

Aim 2



Maximize Treatment Success

Aim 3



Better Treatment Selection

Aim 1: Develop a Prognostic Test


Research Plan

1.1: Tissue based (multi-dimensional) 'omics' test

1.2: Plasma based test

1.3: Decision making analysis

Consumer driven



Minimize Unnecessary Treatment

Aim 2: New Treatments for High-Risk Disease

Research Plan

2.1: **ADEPT:**

Androgen **D**eprivation and **E**rdafitinib pre-**P**rostatectomy **T**rial

2.2: **IMPROvE**

Immune **M**obilisation for **P**ROstate Canc**E**r



Maximize Treatment Success

Aim 3: Companion Predictive Biomarker

Research Plan

3.1: Compound Tumour Suppressor Signature

3.2: Genomic Marker of Androgen Sensitivity




Changing the Natural History

AIM 1 Minimize Unnecessary Treatment



PSA / Tumour Volume



Castration Resistant

AIM 2 Maximize Treatment Success



Death

2nd Line
Hormonal Agents

AIM 3 Better Treatment Selection

